Pathobiology of Lp(a) in calcific aortic valve disease

Calcific aortic valve disease has no drug treatment — only eventual valve replacement. This review investigates a culprit that might change that: lipoprotein(a).

The authors assemble the genetic and molecular case that Lp(a) actively drives valve calcification. The mechanism runs through Lp(a)‘s oxidized-phospholipid cargo and an enzyme, autotaxin, that converts those lipids into pro-calcific signals — accelerating the mineralization that stiffens the valve. Because Lp(a) levels are genetically fixed, this marks a sizable population as predisposed from birth.

The practical takeaway is twofold: measure Lp(a) in patients at risk for aortic valve disease, and watch the Lp(a)-lowering therapies in development as the first potential medical treatment for a disease that currently has none.

We rate the evidence moderate: a well-referenced review consolidating genetic and mechanistic evidence, with one author disclosing industry consulting against a backdrop of mostly public funding. Its clinical significance is high in potential — an effective Lp(a)-lowering drug could become the first medical therapy for calcific aortic valve disease, a growing burden in an aging population — but contingent on trials still to report.